(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 January 2012 (19.01.2012)

PCT

(10) International Publication Number
WO 2012/007280 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *G01N 33/574* (2006.01)

(21) International Application Number:
PCT/EP2011/060930

(22) International Filing Date:
29 June 2011 (29.06.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/359,623 29 June 2010 (29.06.2010) US
10305703.0 29 June 2010 (29.06.2010) EP

(71) Applicant *(for all designated States except US)*: **PIERRE FABRE MEDICAMENT** [FR/FR]; 45, place Abel Gance, F-92100 Boulogne-Billancourt (FR).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **JOUHANNEAUD, Alexandra** [FR/FR]; 83 Impasse de Cizon, F-74130 Bonneville (FR).

(74) Agent: **aWARCOIN, AHNER, TEXIER, LE FORESTIER, CALLON DE LAMARCK, COLLIN, TETAZ, FAIVRE PETIT-Cabinet Regimbeau**; 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: NOVEL ANTIBODY FOR THE DIAGNOSIS AND/OR PROGNOSIS OF CANCER




Figure 9

(57) Abstract: The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.

WO 2012/007280 A1

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*